Thompson Investment Management Inc. Has $5.77 Million Position in Bristol-Myers Squibb (NYSE:BMY)

Thompson Investment Management Inc. lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 101,967 shares of the biopharmaceutical company’s stock after selling 4,229 shares during the quarter. Thompson Investment Management Inc.’s holdings in Bristol-Myers Squibb were worth $5,767,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of BMY. Empowered Funds LLC raised its stake in Bristol-Myers Squibb by 575.9% in the 4th quarter. Empowered Funds LLC now owns 293,943 shares of the biopharmaceutical company’s stock worth $16,625,000 after purchasing an additional 250,451 shares in the last quarter. Forbes J M & Co. LLP raised its stake in Bristol-Myers Squibb by 34.7% in the 4th quarter. Forbes J M & Co. LLP now owns 10,810 shares of the biopharmaceutical company’s stock worth $611,000 after purchasing an additional 2,783 shares in the last quarter. D Orazio & Associates Inc. acquired a new stake in Bristol-Myers Squibb in the 4th quarter worth about $208,000. Apollon Wealth Management LLC raised its stake in Bristol-Myers Squibb by 14.1% in the 4th quarter. Apollon Wealth Management LLC now owns 85,707 shares of the biopharmaceutical company’s stock worth $4,848,000 after purchasing an additional 10,622 shares in the last quarter. Finally, Opinicus Capital Inc. raised its stake in Bristol-Myers Squibb by 2.8% in the 4th quarter. Opinicus Capital Inc. now owns 17,820 shares of the biopharmaceutical company’s stock worth $1,008,000 after purchasing an additional 486 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on BMY. Sanford C. Bernstein began coverage on shares of Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 target price on the stock. Jefferies Financial Group raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their target price for the company from $63.00 to $70.00 in a report on Monday, December 16th. Wolfe Research began coverage on shares of Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Bank of America reissued a “neutral” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Finally, Daiwa America raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Trading Down 0.8 %

BMY opened at $56.96 on Friday. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.10. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The firm has a market capitalization of $115.51 billion, a price-to-earnings ratio of -12.89, a PEG ratio of 2.13 and a beta of 0.45. The company’s 50 day moving average price is $57.56 and its two-hundred day moving average price is $53.75.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. As a group, research analysts predict that Bristol-Myers Squibb will post 6.75 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were given a $0.62 dividend. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.35%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.